Beranda › Karsinoma Sel Skuamosa Kepala dan Leher › Virginia › Richmond
Uji klinis Karsinoma Sel Skuamosa Kepala dan Leher di Richmond, VA
12 studi untuk Karsinoma Sel Skuamosa Kepala dan Leher mencari peserta di lokasi sekitar Richmond (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Menerima pesertaFase 2/3
- Site #0129, Richmond
- Site #0138, Richmond
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Menerima pesertaFase 3
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Menerima pesertaFase 2
- VCU Massey Comprehensive Cancer Center, Richmond
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Menerima pesertaFase 2
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Menerima pesertaFase 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Menerima pesertaFase 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Menerima pesertaFase 2
- Virginia Commonwealth University Massey Cancer Center, Richmond
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Menerima pesertaFase 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Enhancing Oral Cancer Awareness
Menerima pesertaSukarelawan sehat diterima
- Virginia Commonwealth University, Richmond
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Menerima pesertaFase 3
- VCU Massey Cancer Center, Richmond
HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma
Menerima pesertaFase 2
- Bon Secours, Richmond
- Virginia Commonwealth University, Richmond
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Menerima pesertaFase 2
- Massey Cancer Center, Richmond
Uji klinis Karsinoma Sel Skuamosa Kepala dan Leher di kota lain
- Houston, TX47 studi
- Los Angeles, CA42 studi
- Boston, MA40 studi
- New York City, NY39 studi
- Nashville, TN39 studi
- St. Louis, MO28 studi
- Arlington, VA26 studi
- Philadelphia, PA26 studi
- Chicago, IL26 studi
- Atlanta, GA24 studi
- San Antonio, TX22 studi
- New Haven, CT22 studi
Studi lain di Richmond
- Kanker Payudara26 studi
- Kanker Paru Non-Sel Kecil25 studi
- Kanker Prostat19 studi
- Gagal Jantung16 studi
- Kanker Paru14 studi
- Penyakit Kardiovaskular13 studi
- Kanker Kolorektal13 studi
- Penyakit Hati Steatotik12 studi
- Leukemia Mieloid Akut12 studi
- Kanker Metastatik12 studi
- Melanoma11 studi
- Obesitas11 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.